Xoma, a drug royalty specialist, buys another ‘zombie’ biotech
A deal to acquire Alkermes spinout Mural Oncology is Xoma’s fourth since June and the latest evidence of interest in buying and shutting down struggling drugmakers.
Previous Post
This Diet Can Help Lower Your Risk of Alzheimer’s
Next Post
Overviewing the Role of Amyloid-ß Oligomers and Valiltramiprosate in Alzheimer Disease: John Hey, PhD
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago